🇺🇸 FDA

Company profile · Sponsor

Verona

Verona Pharma Ireland Limited

EAF6862 · EMA pharma GB
Pipeline
11
Drugs
0
Patents
0

Quick answer

Verona (EAF6862) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EAF6862
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (11)

Search pipeline →

  1. FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE

    Verona

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial

  2. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  3. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  4. TAMOXENE 20 mg compresse rivestite con film

    Verona

    cystic fibrosis

    phase 2 small molecule active

    1 trial

  5. Teicoplanina Sandoz 200 mg polvere e solvente per soluzione iniettabile o infusione o soluzione orale

    Verona

    cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection

    phase 2 small molecule active

    1 trial

  6. XEOMIN, 100 unità, polvere per soluzione iniettabile

    Verona

    multifocal spasticity of the upper and lower limb due to cerebral palsy

    phase 2 small molecule active

    1 trial

  7. A randomised, open-label, parallel group study to compare the pharmacokinetics and pharmacodynamics of NEODIDRO® 0.266 mg vs DIBASE® 25,000 IU oral doses in male and female patients.

    Verona

    Patients with low Vitamin D plasma level

    phase 1 other active

    1 trial

  8. Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets

    Verona

    patients with secondary progressive MS

    approved small molecule active

    1 trial

  9. Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets, Mayzent 1 mg film-coated tablets, BAF312, BAF312, BAF312

    Verona

    Active progressive multiple sclerosis course after an initial relapse clinical course

    approved small molecule active

    1 trial

  10. Zaredrop 75 mg/ml soluzione orale, Laroxyl 40 mg/ml gocce orali soluzione, FLUOXETINA DOC Generici 20 mg/5 ml Soluzione orale, Zoloft 20 mg/ml concentrato per soluzione orale, Brintellix 20 mg/ml oral drops, solution, Daparox 33,1 mg/ml, gocce orali, soluzione., CITALOPRAM ABC 40 mg/ml gocce orali, soluzione, ESCITALOPRAM DOC 20 mg/ml gocce orali, soluzione

    Verona

    Patients with currently remitted depressive disorders.

    approved small molecule active

    1 trial

  11. Zeposia 0.92 mg hard capsules

    Verona

    Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)

    approved small molecule active

    1 trial

Frequently asked questions

What is Verona?

Verona (EAF6862) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Verona sponsor?

We track 11 ClinicalTrials.gov-linked programs for Verona, including FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Verona company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.